In addition, we demonstrate that the mevalonate pathway and PRC2 vulnerabilities extend to other BAP1-loss-associated malignancies such as uveal melanoma, in which over 95% of metastases have lost BAP1. 6 This evidence concerns the gene BAP1 and uveal melanoma.